NeOnc Technologies releases transcript of investor call on NEO100-01 Phase 2a trial results in recurrent IDH1-mutant high-grade glioma
NTHI•Next regulatory step
Management outlined an FDA meeting to seek a Phase 3 accelerated-approval path using randomization against lomustine, with OS as the primary endpoint.
Trial results and endpoints
Phase 2a met its primary endpoint, with PFS6 of 48.9% versus a 20% historical benchmark; the intent-to-treat population was 24 patients.
Median overall survival measured from recurrence was 26.09 months versus a 6-9 month salvage-therapy benchmark; OS was 60.9% at 12 months.
Investor call on Phase 2a results
NeOnc Technologies hosted an investor call on Aug. 12, 2026 to discuss Phase 2a top-line results for NEO100-01 in recurrent IDH1-mutant high-grade glioma.
Attendees included the CEO, CFO, founder and CSO, chief clinical officer, board directors, scientific advisory board members, and scientific chair.
